포도당과 이소프로테레놀에 의한 시상하부의 소마토스타틴 분비가 갑상선자극호르몬방출호르몬에 의한 갑상선자극호르몬에 미치는 효과

박철영,양인명,오승준,김덕윤,우정택,김성운,김진우,김영설,최영길 대한내분비학회 2000 Endocrinology and metabolism Vol.15 No.4·5

그람양성구균에 대한 Teicoplanin과 Vancomycin의 시험관내 항균력

최태열,김경숙,전용관,서일혜,김정욱,이웅수,안정열,김홍석,정재용,최효선,김덕언,유진우 대한감염학회 1994 감염 Vol.26 No.1

An increasing frequency of methicillin resistant S. aureus(MRSA), methicillin resistant coagulase negative staphylococci(MRCNS) and Enterococcal infection have been observed in recent years. Teicoplanin is a new glycopeptide antibiotic obstained from the Actinoplanes teicomycetius. The molecular structure and spectrum of antimicrobial activity of teicoplanin is simillar to those of vancomycin, and has been reported to have an excellent in vitro and in vivo effect against various gram-positive infections. Therefore, we evaluated the in vitor susceptibility of gram positive cocci, such as, S. aureus, coagulase negative Staphylococci(CNS), and Enterococci to teicoplanin and vancomycin. The total 253 strains consisted of MSSA(40), MRSA(53), MSCNS(47), MRCNS(48), and Enterococci(65). They were assayed by disc diffusion and agar dilution. During the study, 57% of S. aureus and 49% of CNS showed resistance to methicillin. The inhibitory diameter of teicoplanin was 15-20mm in MSSA, 12-19mm in MRSA, 13-24mm in MSCNS, 11-23mm in MRCNS, and 15-22mm in Enterococci respectively, and showed sensitivity in all but 8 strains(3.2%). The range of the minimum inhibitory concentration (MIC) of teicoplanin to MSSA, MRSA, MSCNS, MRCNS and Enterococci were 9.12-2.0㎍/ml, 0.25-2.0㎍/ml, & 0.25-32㎍/ml, 0.12-1.0㎍/ml respectively. One case of S. haemolyticus was resistant to teicoplanin (32㎍/ml) by the agar dilution method. Eight minor (3.2%) and one major(0.4%) error was observed when the MIC and disk diffusion data were correlated with teicoplanin. As for vancomycin the inhibitory diameter was 17-21mm in MSSA, 15-21mm in MRSA, 18-26mm in MSCNS, 18-25mm in MRCNS, and 16-22mm in Enterococci respectively. The range of the MIC of vancomycin to MSSA, MRSA, MSCNS, MRCNS, and Enterococci were 0.25-1.0㎍/ml, 0.25-4.0㎍/ml, 0.5-2.0㎍/ml and 0.5-2.0㎍/ml respectively. One minor error (0.4%) was seen with the vancomycin disk. The MIC90 of MSSA and MRSA exhibited the same results in teicoplanin (1.0㎍/ml, 1.0㎍/ml), and vancomycin(2.0㎍/ml, 2.0㎍/ml). MSCNS and MRCNS exhibited greater MIC90 with teicoplanin(4.0㎍/ml, 8.0㎍/ml) than vancomycin(2.0㎍/ml, 2.0㎍/ml). Incontrase Enterococci were more susceptible to teicoplanin(0.5㎍/ml) than to vancomucin (2.0㎍/ml). Results from this analysis indicated that both teicoplanin and vancomycin were very excellent for gram positive infections, especially those resistant to methicillin.

자폐인의 치아우식증에 관한 통계학적 연구

최영철,이긍호,류영덕 大韓小兒齒科學會 1999 大韓小兒齒科學會誌 Vol.26 No.1

The purpose of this study was to make a comprehensive study and to provide information about the dental caries of autistic persons, and to aid improvement of their oral health. The authors examined intraorally 114 (male; 87, female;27) autistic persons and 119 (male;68, female;51) normal persons as control group. The obtained results were as follows: 1. Autistic persons were found to have lower dft rate than normal persons. 2. There was no significant difference in dental caries incidence between male and female autistic persons. 3. Institutionalized autistic persons were found to have lower dental caries incidence of deciduous teeth than non-institutionalized autistic persons. 4. Autistic persons whose parent's occupation is laborer were found to have higher dft index than those whose parent's occupation is private business or employee.

FCL(5-FU, Carboplatin, Leucovorin) 항암 화학요법에서 Gm-CSF의 효과

최지영,김현수,김종숙,박상준,윤환중,조덕연,남상륜,김삼용 忠南大學校 癌共同硏究所 1998 癌共同硏究所 硏究誌 Vol.2 No.1

Background: One of the major side effects of cancer chemotherapy is myelosuppression. Neutropenia and/or thrombocytopenia are dose-limiting factors in chemotherapy. Colony-stimulating factor induces proliferation and functional maturation of hematopoietic progenitor cells. GM-CSF is primarily active on progenitor cells of granulocytic and monocytic lineage. Methods: Fifteen patients with histologically proven malignancy diagnosed at Chungnam National University Hospital from January 1993 to August 1995 were included in this study. We could evaluate the clinical efficacy of GM-CSF in 13 patients undergoing FCL(5-FU, Carboplatin and Leucovorin) chemotherapy; the first cycles involved no GM-CSF while the second cycles involved GM-CSF on day 6 through 15 of chemotherapy. Results: 1) The subjects were fifteen patients in all, there were five patients with head and neck cancer, which was the most common types of maligancy. There were four patients with colon cancer, two patients with stomach cancer, and one patient with breast cancer, gallbladder cancer, cervix cancer and cholangiocarcinoma respectively, two patients, who did not complete two cycles of chemotherapy were excluded. 2) Age distribution was from 38 years to 78 years with a median age of 57. 3) In FCL chemotherapy cycles with GM-CSF, the duration of neutropenia(<500/μL) was 0.5±0.3 day, while FCL chemotherapy cycles without GM-CSF, it was 2.9±0.7 day(P=0.008). 3) There was no significant difference in platelet count between the two chemotherapy cycles(P=0.133). 4) Febrile duration without GM-CSF was 4.9±2.1 day, but with GM-CSF the duration was 1.3±0.7 day, which was significantly different(P=0.003). The duration of antibiotics use with GM-CSF was 1.7±1.2 day and without GM-CSF was 6.8±3.2 day, also significantly different(P=0.002). But hospital stay between the two cycles were not significantly different(P=0.064). Conclusion: GM-CSF was effective in preventing or restoring bone marrow depression after FCL chemotherapy.

건조된 한약재의 유전자 분석 가능성 연구

崔湖榮,任德彬 대한본초학회 2001 大韓本草學會誌 Vol.16 No.1

The isolation of DNA from crude drug has been described by numerous authors, each contributing a different method to overcome the problems that arise when extracting DNA. Fresh of frozen tissue is usually used as a source of DNA for PCR and RAPD analysis. A SDS method for rapid purification of DNA from variety of herbal crude drug, extracting from samples as small as 1㎎, has been optimized. I reached the following conclusion. The yield of DNA was declined after 3 and 4 days drying at 60℃. However, the DNA isolated from all sample at 60℃ in oven was suitable for analysis with random 10-mer primer as the primer. Similar results were obtained with crude drug Angelicae Gigantis Radix from the different drying time. I think that this result can not only be used as a way to discriminate crude drug but it can be also utilized to control the quality of crude drug and the distribution channel in the future.

[논문]보양조건 및 타설주기를 고려한 매스 콘크리트 구조물의 수화열 해석

이영호,서기영,최덕락,엄장섭,진치섭* 釜山大學校生産技術硏究所 2004 生産技術硏究所論文集 Vol.63 No.-

콘크리트 구조물의 공용수명은 콘크리트 재료의 초기에 발생하는 수화열에 의해 아주 큰 영향을 받는다. 수화열은 콘크리트의 열전달 및 열응력 특성으로 결정되어지는 온도균열지수를 통해 분석되고 있다. 본 연구에서는 이러한 온도균열 지수의 분석을 통해 매스 콘크리트 구조물의 시공시 적절한 시벤트 종류, 보양방법,타설주기 및 타설높이 둥 최적의 시공방안 구하는데 도움을 주어 향후 시공 예정인 매스 콘크리트 구조물에 발생 가능한 온도균열을 미리 예측하여 이를 방지하기 위한 시공 방안을 제안하는데 그 목적을 두고 있다.

폐경기 증후군 환자에서 Cyclofenil의 치료 효과

김덕윤,고은미,우정택,양인명,김진우,김영설,김광원,최영길 최신의학사 1992 最新醫學 Vol.35 No.10

악성종양에서 혈청 Intercellular Adhesion Molecule-1의 혈청

조덕연,김현수,박상준,김종숙,최지영,윤환중,김삼용 충남대학교 의과대학 지역사회의학연구소 1995 충남의대잡지 Vol.22 No.1

Intercellular adhesion molecule-1 (ICAM-1) is a glycoprotein serving as ligands for leukocyte intergrin receptors, i.e. LFA-1, MAC-l. It has been suggested that the expression of ICAM-1 and the levels of circulating ICAM-1 were increased in several malignancies. We measured serum ICAM-1 by ELISA in patients with stomach cancer (n=25), acute lymphoblastic leukemia (n=7), non-Hodgkin's lymphoma (n=14), and metastasis of unknown origin (n=5). Serum levels of circulating ICAM-1 in all malignancies were significantly higer than in normal controls. And serum level of ICAM-1 in stomach cancer ptients having metastatic disease was higher than in patients with localized disease (p=0.027). These results suggest that elevated serum ICAM-1 is a rather common feature for malignancies, not unique for certain types of cancer such as malignant melanoma. It remains to be clalified whether marked increase of serum ICAM-1 in metastatic stomach cancers simply reflect tumor burden or this molecule plays a role in progression in stomach cancer.

급성골수백혈병에 대한 관해유도화학요법 후의 Granulocyte Colony-stimulating Factor의 효과

윤환중,최지영,전의건,길준영,조덕연,김삼용 충남대학교 의과대학 지역사회의학연구소 1993 충남의대잡지 Vol.20 No.2

Granulocyte colony-stimulating factor(G-CSF) have been shown to hasten the recovery of neutropenia following anti-cancer chemotherapy. There are controversial opinions on the use of G-CSF in acute myelogenous leukemia(AML) because clonogenic studies have shown that G-CSF stimulates leukemic colonies as well as granulocyte colonies. In this study, we evaluated the effectiveness and safety of recombinant human G-CSF after induction chemotherapy with DAV regimen(Ara-C 100mg/㎡ day 1-8, Doxorubicin 45mg/㎡ day 3-5, VP-16 100mg/㎡ day 6-8) in 9 patients with AML. G-CSF therapy(200 ㎍/㎡/day) was begun 2 days after the end of chemotherapy and continued for 10 days. 17 AML patients who recieved the same chemotherapy before the onset of this study were used as historical control. G-CSF shortened the duration of granulocytopenia (less than 500/㎣) significantly (13 vs 23 days, p<0.001), but it had no effect on platelet recovery. Although the incidence of febrile episodes was almost the same, the duration of febrile episodes was shorter in the group treated with G-CSF( 5 vs 12 days, p=0.03). There was no evidence that G-CSF accelerated the regrowth of leukemic cells and the complete remission rates between the 2 groups were not different. These results show that G-CSF accelerates the recovery of granulocytopenia and shortens the febrile days after chemotherpy in patients with AML, without affecting the regrowth of leukemic cells.

급성골수성백혈병 환자에서 DAV 병용화학요법 후의 장기생존율

김삼용,최지영,윤환중,전의건,길준영,조덕연 충남대학교 의과대학 지역사회의학연구소 1993 충남의대잡지 Vol.20 No.2

Background : Despite substantial progress, the treatment of acute myeloid leukemia(AML) has produced complete remission in 60-80% of patients receiving induction chemotherapy, and median remission duration is about 12 months and only 20% to 35% of patients undergoing consolidation chemotherapy achieve long-term disease-free survival(DFS). We evaluated the long-term outcome of AML patients treated with doxorubicin/Ara-C/VP-16(DAV) induction chemotherapy and consolidation/intensification therapy. Method : Induction therapy : From January 1986 to December 1991, twenty three patients with previously untreated acute myelogenous leukemia received a course of 45mg/㎡ doxorubicin daily intravenously for three consecutive days with Ara-C at 100mg/㎡ by continuous intravenous infusion for eight consecutive days and VP-16 at 100mg/㎡ daily intravenously for three consecutive days. A second course of treatment was started if leukemia persisted on 22 days after treatment. Post-remission therapy : Three to six cycles were given at three or four months interval with Ara-C/doxorubicin/VP-16 regimen or other therapy. Results : Twenty two pateints were evaluable and complete remission was achieved in 16 of 22(73%). Median duration of complete remission was 8 months. The relapse rate was 81% and 63% relapsed in first year. 4-year survival rate of patients entering complete remission(n=16) was 19% and median survival duration was 14.5 months. The postremission chemotherapy was the only significant prognostic factor influencing long term disease free survival. No significant correlation was observed between the probability of survival and age (40< or >40), sex, FAR subgroup, and leukocyte count at diagnosis. The median survival duration were 21 months and 12.5 months for patients who received, or not received postremission chemotherapy respectively(P=0.035). Conclusion : Our results show that DAV combination chemotherapy is a useful therapeutic regimen in remission induction and postremission chemotherapy offering survival advantage in patients with AML entering complete remission.